U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C13H15Cl2NO.ClH
Molecular Weight 308.631
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CLORGILINE HYDROCHLORIDE

SMILES

Cl.CN(CCCOC1=C(Cl)C=C(Cl)C=C1)CC#C

InChI

InChIKey=BBAZDLONIUABKI-UHFFFAOYSA-N
InChI=1S/C13H15Cl2NO.ClH/c1-3-7-16(2)8-4-9-17-13-6-5-11(14)10-12(13)15;/h1,5-6,10H,4,7-9H2,2H3;1H

HIDE SMILES / InChI

Molecular Formula C13H15Cl2NO
Molecular Weight 272.17
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Clorgiline is a monoamine oxidase (MAO) inhibitor. Specifically, it is an irreversible and selective inhibitor of MAO-A. Clorgiline was under investigation for antidepressant and anxiolytic potential but has never been marketed, likely due to efficacy concerns. It continues to see routine use as a molecular probe in biomedical research examining a number of neurological disease and cancer models. In addition to inhibiting the MAO-A receptor, it has also been found to bind to the sigma1 receptor, and with high affinity to the I2 imidazoline receptor.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P21397
Gene ID: 4128.0
Gene Symbol: MAOA
Target Organism: Homo sapiens (Human)
1.4 nM [IC50]
Target ID: Q99720|||Q7Z653
Gene ID: 10280.0
Gene Symbol: SIGMAR1
Target Organism: Homo sapiens (Human)
Target ID: Q9Y2I1|||Q9UFW3
Gene ID: 11188.0
Gene Symbol: NISCH
Target Organism: Homo sapiens (Human)
1.4 nM [IC50]
Target ID: Q99720|||Q7Z653
Gene ID: 10280.0
Gene Symbol: SIGMAR1
Target Organism: Homo sapiens (Human)
Target ID: Q9Y2I1|||Q9UFW3
Gene ID: 11188.0
Gene Symbol: NISCH
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Possible development of the serotonin syndrome in man.
1982 Jul
Selective and nonselective monoamine oxidase inhibitors: behavioral disturbances during their administration to depressed patients.
1982 May
Brain monoamine oxidase in suckling rabbits treated with organophosphorus compound. I. Acute intoxication.
1984 Mar-Apr
Treatment with clorgyline and pargyline differentially decreases clonidine-induced hypotension and bradycardia.
1984 Sep
Inhibition of monoamine oxidase activity by phenylpropanolamine, an anorectic agent.
1986 Feb
Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat.
1987 Sep
Dissociation of norepinephrine turnover from alpha-2 responses after clorgiline.
1988 Jan
Evaluation of the effects of inhibition of monoamine oxidase and senescence on methamphetamine-induced neuronal damage.
1991
Differential trace amine alterations in individuals receiving acetylenic inhibitors of MAO-A (clorgyline) or MAO-B (selegiline and pargyline).
1998
Inhibition of MAO-A fails to alter cocaine-induced increases in extracellular dopamine and norepinephrine in rat nucleus accumbens.
2001 Mar 5
Effects of elevated serotonin levels on patterns of GAP-43 expression during barrel development in rat somatosensory cortex.
2002 Dec 15
Differential substrate specificity of monoamine oxidase in the rat heart and renal cortex.
2003 Jul 11
Monoamine oxidase A rather than monoamine oxidase B inhibition increases nicotine reinforcement in rats.
2006 Dec
The antioxidant anethole dithiolethione inhibits monoamine oxidase-B but not monoamine oxidase A activity in extracts of cultured astrocytes.
2006 May
Anti-oncogenic and pro-differentiation effects of clorgyline, a monoamine oxidase A inhibitor, on high grade prostate cancer cells.
2009 Aug 20
Drug discovery for Duchenne muscular dystrophy via utrophin promoter activation screening.
2011
Homoisoflavonoids: natural scaffolds with potent and selective monoamine oxidase-B inhibition properties.
2011 Apr 14
Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease.
2011 Dec 22
Chromone, a privileged scaffold for the development of monoamine oxidase inhibitors.
2011 Jul 28
Synthesis of three novel fluorine-18 labeled analogues of L-deprenyl for positron emission tomography (PET) studies of monoamine oxidase B (MAO-B).
2011 Oct 27
Synthesis and study of a series of 3-arylcoumarins as potent and selective monoamine oxidase B inhibitors.
2011 Oct 27
The monoamine oxidase A inhibitor clorgyline is a broad-spectrum inhibitor of fungal ABC and MFS transporter efflux pump activities which reverses the azole resistance of Candida albicans and Candida glabrata clinical isolates.
2012 Mar
Piperine potentiates the antidepressant-like effect of trans-resveratrol: involvement of monoaminergic system.
2013 Dec
A novel selective LSD1/KDM1A inhibitor epigenetically blocks herpes simplex virus lytic replication and reactivation from latency.
2013 Feb 5
Acute effects of resveratrol to enhance cocaine-induced dopamine neurotransmission in the striatum.
2013 May 10
Screening of a chemical library reveals novel PXR-activating pharmacologic compounds.
2015 Jan 5
Evaluation of metabolism dependent inhibition of CYP2B6 mediated bupropion hydroxylation in human liver microsomes by monoamine oxidase inhibitors and prediction of potential as perpetrators of drug interaction.
2015 Mar 25
Patents

Sample Use Guides

Patients suffering depression were administered 30 mg/day of Clorgyline for three or more weeks. However, this regime produced negligible changes in trace amine excretion including, phenylethylamine, para-tyramine, and meta-tyramine.
Route of Administration: Unknown
T24, HCT116, and HL60 cells were incubated overnight and treated with 1 micro-, 0.3 µM or 0.1 µM of 5-Aza-CdR, respectively for 24 hours. After removal of 5-Aza-CdR, cells were treated with 10 µM clorgyline every day for 21 days. Multiple doses of clorgyline were tested: 1 µM, 10 µM, and 100 µM. Clorgyline was found to impair cell growth in a dose-dependent manner and the optimal dose was identified as 10 microM.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:03:24 GMT 2023
Edited
by admin
on Fri Dec 15 15:03:24 GMT 2023
Record UNII
H38V165133
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CLORGILINE HYDROCHLORIDE
Common Name English
N-(3-(2,4-DICHLOROPHENOXY)PROPYL)-N-METHYL-2-PROPYNYLAMINE HYDROCHLORIDE
Systematic Name English
2-PROPYN-1-AMINE, N-(3-(2,4-DICHLOROPHENOXY)PROPYL)-N-METHYL-, HYDROCHLORIDE (1:1)
Systematic Name English
CLORGYLINE HYDROCHLORIDE
Common Name English
NSC-759306
Code English
Code System Code Type Description
ECHA (EC/EINECS)
241-760-5
Created by admin on Fri Dec 15 15:03:24 GMT 2023 , Edited by admin on Fri Dec 15 15:03:24 GMT 2023
PRIMARY
PUBCHEM
28767
Created by admin on Fri Dec 15 15:03:24 GMT 2023 , Edited by admin on Fri Dec 15 15:03:24 GMT 2023
PRIMARY
EPA CompTox
DTXSID3045778
Created by admin on Fri Dec 15 15:03:24 GMT 2023 , Edited by admin on Fri Dec 15 15:03:24 GMT 2023
PRIMARY
NSC
759306
Created by admin on Fri Dec 15 15:03:24 GMT 2023 , Edited by admin on Fri Dec 15 15:03:24 GMT 2023
PRIMARY
CAS
17780-75-5
Created by admin on Fri Dec 15 15:03:24 GMT 2023 , Edited by admin on Fri Dec 15 15:03:24 GMT 2023
PRIMARY
DRUG BANK
DBSALT002700
Created by admin on Fri Dec 15 15:03:24 GMT 2023 , Edited by admin on Fri Dec 15 15:03:24 GMT 2023
PRIMARY
FDA UNII
H38V165133
Created by admin on Fri Dec 15 15:03:24 GMT 2023 , Edited by admin on Fri Dec 15 15:03:24 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE